FDA plans to speed path to approval for some gene therapies, starting with hemophilia

Hemophilia is the first disease the FDA will target with its new policy.
Source: AP Photo/Eric Risberg

WASHINGTON — The Food and Drug Administration will soon be alerting companies that certain gene therapies in development can qualify for less arduous review at the agency, Commissioner Scott Gottlieb said Tuesday.

Specifically, gene therapies for , a rare disease in which blood doesn’t

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPsychology
Opinion: In A Medical Emergency, Who In Your Social Network Will Call For Help Quickest?
Applying the "strength of weak ties" theory to medicine, a weakly connected familiar in your social network can be the outside voice of reason who isn't afraid to call for…
STAT3 min readScience
Why Are Elite Athletes Different Than The Rest Of Us? Take A Look At Their Microbes
Elite athletes really are different from you and me. Or, at least their gut microbes are. Scientists who analyzed stool samples of 15 runners a week before and after they competed in the 2015 Boston Marathon found unusually high levels of one particu
STAT2 min read
How The Kaiser-Johns Hopkins Analysis Was Done
Kaiser Health News' analysis of surgeons’ prescribing habits was done in collaboration with researchers at Johns Hopkins School of Public Health.